Continuity Biosciences
Manufacturing · Florida, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
8476 Lindrick Ln, Bradenton, Florida, 34...Revenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Feb
Mar
Apr
May
Jun
Jul
ZI Rank
1
1
1
1
1
1
About Continuity Biosciences
Continuity Biosciences, founded in 2024, is a biotechnology company developing advanced drug delivery technologies and combination therapy platforms for chronic and complex diseases.Explore more
Continuity Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Continuity Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Funding: Get notified immidiatlly once Continuity Biosciences has new funding data
Click to see if Continuity Biosciences had a recent Job posting/layoffs
Continuity Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Website visits: Recent activity has been detected on your website
Product Launch: Get notified when Continuity Biosciences launches new products
Check if Continuity Biosciences has recently received funding, and reach out quickly before it becomes old news!
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Continuity Biosciences
Earning: See what the market has to say on Continuity Biosciences recently announced quarterly report
Check out if Continuity Biosciences is spiking on competitors!
Recommended Actions
Reach out to Masked Content who joined Continuity Biosciences as Masked Content
Find 2 more new buyers
Company Profile Activity
Activity Insights
Continuity Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Continuity Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Continuity Biosciences.
Continuity Biosciences financials insights
Gather financial insights about Continuity Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2025
Stock/Share Issuance
$8.4M
Continuity Biosciences Tech Stack
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Mergers & Acquisitions (M&A)
Mergers & Acquisitions, Acquisitions, Mergers
Mergers & Acquisitions (M&A)
Continuity Biosciences News & Media
Continuity Biosciences Announces First-in-Human Clinical Trial of Precision Drug Delivery Platform for Pancreatic Cancer
Study now open for enrollment at leading academic medical centers CARY, N.C. and BRADENTON, Fla., May 20, 2026 /PRNewswire/ -- Continuity Biosciences, LLC, a clinical-stage biotechnology company advancing precision drug delivery platforms, today announced the initiation of a Phase I, first-in-human clinical trial evaluating gemcitabine delivered via its iontophoretic oncology platform (IOP) for the treatment of pancreatic cancer. The study, listed on ClinicalTrials.gov (NCT07481383), is now openContinuity Biosciences and Breakthrough T1D Collaborate to Advance NICHE® Cell-Therapy Platform Toward First-in-Human Study
Collaboration supports IND-enabling development and a planned Phase 1/2a first-in-human clinical study in type 1 diabetes CARY, N.C. and NEW YORK, March 24, 2026 /PRNewswire/ -- Continuity Biosciences and Breakthrough T1D, the leading global type 1 diabetes (T1D) advocacy organization, today announced a strategic collaboration to advance Continuity's NICHE® cell-therapy platform toward a planned first-in-human clinical study for people living with T1D. The effort is supported through BreakthrougContinuity Biosciences Appoints Josephine Torrente and Joseph DeSimone, PhD to Board of Directors
BRADENTON, Fla., Aug. 6, 2025 /PRNewswire/ -- Continuity Biosciences, a company pioneering next-generation combination product drug delivery, today announced the appointment of two highly distinguished leaders to its Board of Directors: Josephine M. Torrente, Director at Hyman, Phelps &...
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Continuity Biosciences
Sign Up For FreeTo access detailed company insights
Continuity Biosciences, founded in 2024, is a biotechnology company developing advanced drug delivery technologies and combination therapy platforms for chronic and complex diseases.... Read More
